{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:25:42Z","timestamp":1785507942692,"version":"3.56.0"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse of the National Institutes of Health","doi-asserted-by":"publisher","award":["R33DA045851"],"award-info":[{"award-number":["R33DA045851"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse of the National Institutes of Health","doi-asserted-by":"publisher","award":["R01DA051067"],"award-info":[{"award-number":["R01DA051067"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse of the National Institutes of Health","doi-asserted-by":"publisher","award":["P30DA035772"],"award-info":[{"award-number":["P30DA035772"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Innovative strategies remain necessary to increase utilization of medications for opioid use disorder (MOUD), an effective approach to reduce overdoses and deaths. The hub and spoke (HS) model is increasingly used to improve MOUD treatment, yet the impact is relatively unknown. We assessed the effectiveness of Washington State's hub and spoke (WA-HS) model on 6-month outcomes of MOUD continuity and health care utilization.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We analyzed 25 368 adult Medicaid beneficiaries with new MOUD episodes in 2016-2019, comparing HS and non-HS cohorts in the 6\u2005months after starting MOUD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Across both cohorts, 26% stayed on MOUD for 6\u2005months, and within 6\u2005months of MOUD initiation, 42% had an emergency department (ED) visit, 14% had any hospitalization, and 13% entered intensive substance use treatment. No significant differences were found between cohorts for all outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our null findings likely reflect the complexity of the OUD crisis, the many needs of people with OUD that require flexible approaches at the individual and systems levels, and the WA-HS focus on MOUD initiation. Findings highlight the need to ensure HS models incorporate strategies to address MOUD continuity to drive long-term recovery for people with OUD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/haschl\/qxaf157","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T18:58:16Z","timestamp":1755025096000},"source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness of Washington State's hub and spoke model to improve opioid use disorder outcomes"],"prefix":"10.1093","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9234-5641","authenticated-orcid":false,"given":"Sharon","family":"Reif","sequence":"first","affiliation":[{"name":"Institute for Behavioral Health, Schneider Institutes for Health Policy and Research, Heller School for Social Policy and Management, Brandeis University , 415 South Street, Waltham, MA 02453 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5470-0307","authenticated-orcid":false,"given":"Maureen T","family":"Stewart","sequence":"additional","affiliation":[{"name":"Institute for Behavioral Health, Schneider Institutes for Health Policy and Research, Heller School for Social Policy and Management, Brandeis University , 415 South Street, Waltham, MA 02453 ,","place":["United States"]},{"name":"Department of Health Law, Policy and Management, Boston University School of Public Health , 715 Albany Street, Boston, MA 02118 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0455-6762","authenticated-orcid":false,"given":"Shay M","family":"Daily","sequence":"additional","affiliation":[{"name":"Institute for Behavioral Health, Schneider Institutes for Health Policy and Research, Heller School for Social Policy and Management, Brandeis University , 415 South Street, Waltham, MA 02453 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4959-9567","authenticated-orcid":false,"given":"Lee","family":"Panas","sequence":"additional","affiliation":[{"name":"Institute for Behavioral Health, Schneider Institutes for Health Policy and Research, Heller School for Social Policy and Management, Brandeis University , 415 South Street, Waltham, MA 02453 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1009-4878","authenticated-orcid":false,"given":"Grant A","family":"Ritter","sequence":"additional","affiliation":[{"name":"Institute for Behavioral Health, Schneider Institutes for Health Policy and Research, Heller School for Social Policy and Management, Brandeis University , 415 South Street, Waltham, MA 02453 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0286-4860","authenticated-orcid":false,"given":"Mary F","family":"Brolin","sequence":"additional","affiliation":[{"name":"Institute for Behavioral Health, Schneider Institutes for Health Policy and Research, Heller School for Social Policy and Management, Brandeis University , 415 South Street, Waltham, MA 02453 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret T","family":"Lee","sequence":"additional","affiliation":[{"name":"Institute for Behavioral Health, Schneider Institutes for Health Policy and Research, Heller School for Social Policy and Management, Brandeis University , 415 South Street, Waltham, MA 02453 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0887-8611","authenticated-orcid":false,"given":"Jennifer J","family":"Wicks","sequence":"additional","affiliation":[{"name":"Institute for Behavioral Health, Schneider Institutes for Health Policy and Research, Heller School for Social Policy and Management, Brandeis University , 415 South Street, Waltham, MA 02453 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"2025083005212371200_qxaf157-B1","author":"Centers for Disease Control and Prevention"},{"key":"2025083005212371200_qxaf157-B2","doi-asserted-by":"publisher","DOI":"10.15620\/cdc:135849","volume-title":"Drug Overdose Deaths in the United States, 2002\u20132022","author":"Spencer","year":"2024"},{"issue":"2","key":"2025083005212371200_qxaf157-B3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1176\/appi.ps.201300256","article-title":"Medication-assisted treatment with buprenorphine: assessing the evidence","volume":"65","author":"Thomas","year":"2014","journal-title":"Psychiatr Serv"},{"key":"2025083005212371200_qxaf157-B4","doi-asserted-by":"publisher","first-page":"25310","DOI":"10.17226\/25310","volume-title":"Medications for Opioid Use Disorder Save Lives","author":"NASEM","year":"2019"},{"issue":"12","key":"2025083005212371200_qxaf157-B5","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1038\/s41380-018-0094-5","article-title":"Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis","volume":"24","author":"Ma","year":"2019","journal-title":"Mol Psychiatry"},{"key":"2025083005212371200_qxaf157-B6","doi-asserted-by":"publisher","DOI":"10.1377\/forefront.20230405.301023","article-title":"The recommended minimum length of pharmacotherapy for opioid use disorder is actually more than a year, but more research is needed","author":"Duffy","year":"2023","journal-title":"Health Aff Forefr"},{"key":"2025083005212371200_qxaf157-B7","doi-asserted-by":"publisher","first-page":"103786","DOI":"10.1016\/j.drugpo.2022.103786","article-title":"Has the treatment gap for opioid use disorder narrowed in the U.S.?: a yearly assessment from 2010 to 2019","volume":"110","author":"Krawczyk","year":"2022","journal-title":"Int J Drug Policy"},{"key":"2025083005212371200_qxaf157-B8","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1177\/29767342241303583","article-title":"Examining the impact of eliminating the X waiver on buprenorphine dispensation in 63 counties in Pennsylvania","volume":"46","author":"Bilden","year":"2025","journal-title":"Subst Use Addict J"},{"issue":"8","key":"2025083005212371200_qxaf157-B9","doi-asserted-by":"publisher","first-page":"e2425999","DOI":"10.1001\/jamanetworkopen.2024.25999","article-title":"Buprenorphine prescribing characteristics following relaxation of X-waiver training requirements","volume":"7","author":"Christine","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"7","key":"2025083005212371200_qxaf157-B10","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.cjca.2018.04.029","article-title":"The spoke-hub-and-node model of integrated heart failure care","volume":"34","author":"Huitema","year":"2018","journal-title":"Can J Cardiol"},{"issue":"5","key":"2025083005212371200_qxaf157-B11","first-page":"1","article-title":"Hub-and-spoke models of care for chronic pain","volume":"2","author":"Barbara","year":"2022","journal-title":"Can J Health Technol"},{"issue":"4","key":"2025083005212371200_qxaf157-B12","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/ADM.0000000000000310","article-title":"Vermont hub-and-spoke model of care for opioid use disorder: development, implementation, and impact","volume":"11","author":"Brooklyn","year":"2017","journal-title":"J Addict Med"},{"issue":"2","key":"2025083005212371200_qxaf157-B13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/adm.0000000000000200","article-title":"Using a learning collaborative strategy with office-based practices to increase access and improve quality of care for patients with opioid use disorders","volume":"10","author":"Nordstrom","year":"2016","journal-title":"J Addict Med"},{"key":"2025083005212371200_qxaf157-B14","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jsat.2018.11.003","article-title":"Assessment of medication for opioid use disorder as delivered within the Vermont hub and spoke system","volume":"97","author":"Rawson","year":"2019","journal-title":"J Subst Abuse Treat"},{"key":"2025083005212371200_qxaf157-B15","doi-asserted-by":"publisher","first-page":"11782218211039781","DOI":"10.1177\/11782218211039781","article-title":"Barriers for implementing the hub and spoke model to expand medication for opioid use disorder: a case study of Montana","volume":"15","author":"Green","year":"2021","journal-title":"Subst Abuse"},{"issue":"4","key":"2025083005212371200_qxaf157-B16","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1080\/08897077.2020.1846149","article-title":"System-level factors shaping the implementation of \u201chub and spoke\u201d systems to expand MOUD in rural areas","volume":"42","author":"Snell-Rood","year":"2021","journal-title":"Subst Abus"},{"key":"2025083005212371200_qxaf157-B17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jsat.2019.05.005","article-title":"West Virginia's model of buprenorphine expansion: preliminary results","volume":"108","author":"Winstanley","year":"2020","journal-title":"J Subst Abuse Treat"},{"key":"2025083005212371200_qxaf157-B18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jsat.2016.12.010","article-title":"Long-term retention in office based opioid treatment with buprenorphine","volume":"74","author":"Weinstein","year":"2017","journal-title":"J Subst Abuse Treat"},{"key":"2025083005212371200_qxaf157-B19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jsat.2015.06.010","article-title":"Office-Based Opioid Treatment with Buprenorphine (OBOT-B): statewide implementation of the Massachusetts Collaborative Care Model in community health centers","volume":"60","author":"LaBelle","year":"2016","journal-title":"J Subst Abuse Treat"},{"key":"2025083005212371200_qxaf157-B20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jsat.2019.07.007","article-title":"The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders","volume":"108","author":"Reif","year":"2020","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"2025083005212371200_qxaf157-B21","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/j.0887-378X.2004.00325.x","article-title":"Diffusion of innovations in service organizations: systematic review and recommendations","volume":"82","author":"Greenhalgh","year":"2004","journal-title":"Milbank Q"},{"key":"2025083005212371200_qxaf157-B22","doi-asserted-by":"publisher","first-page":"111125","DOI":"10.1016\/j.drugalcdep.2024.111125","article-title":"Expanding access to medication treatment for opioid use disorders: findings from the Washington State hub and spoke effort","volume":"256","author":"Stewart","year":"2024","journal-title":"Drug Alcohol Depend"},{"key":"2025083005212371200_qxaf157-B23","doi-asserted-by":"publisher","first-page":"209544","DOI":"10.1016\/j.josat.2024.209544","article-title":"Relationship of hub and treatment characteristics with client outcomes in the initial Washington State hub and spoke cohort","volume":"168","author":"Reif","year":"2025","journal-title":"J Subst Use Addict Treat"},{"key":"2025083005212371200_qxaf157-B24","author":"Trochim"},{"issue":"4","key":"2025083005212371200_qxaf157-B25","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s10742-014-0123-z","article-title":"Using propensity scores in difference-in-differences models to estimate the effects of a policy change","volume":"14","author":"Stuart","year":"2014","journal-title":"Health Serv Outcomes Res Methodol"},{"issue":"3","key":"2025083005212371200_qxaf157-B26","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An Introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"2025083005212371200_qxaf157-B27","author":"National Quality Forum"},{"key":"2025083005212371200_qxaf157-B28","author":"U.S. Department of Agriculture, Economic Research Service"},{"key":"2025083005212371200_qxaf157-B29","author":"Robert Graham Center"},{"issue":"3","key":"2025083005212371200_qxaf157-B30","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/ADM.0000000000001104","article-title":"Improving research on racial disparities in access to medications to treat opioid use disorders","volume":"17","author":"Mark","year":"2023","journal-title":"J Addict Med"},{"issue":"6","key":"2025083005212371200_qxaf157-B31","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"1","key":"2025083005212371200_qxaf157-B32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1001\/jama.2014.7523","article-title":"The intention-to-treat principle: how to assess the true effect of choosing a medical treatment","volume":"312","author":"Detry","year":"2014","journal-title":"JAMA"},{"issue":"3","key":"2025083005212371200_qxaf157-B33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4103\/2229-3485.83221","article-title":"Intention-to-treat concept: a review","volume":"2","author":"Gupta","year":"2011","journal-title":"Perspect Clin Res"},{"key":"2025083005212371200_qxaf157-B34","author":"SAS Institute Inc"},{"issue":"1","key":"2025083005212371200_qxaf157-B35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jsat.2012.02.001","article-title":"Performance contracting and quality improvement in outpatient treatment: effects on waiting time and length of stay","volume":"44","author":"Stewart","year":"2013","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"2025083005212371200_qxaf157-B36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1176\/appi.ps.201600475","article-title":"Can we pay for performance in behavioral health care?","volume":"68","author":"Stewart","year":"2017","journal-title":"Psychiatr Serv"},{"key":"2025083005212371200_qxaf157-B37","doi-asserted-by":"publisher","first-page":"108329","DOI":"10.1016\/j.jsat.2021.108329","article-title":"Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings","volume":"126","author":"Krawczyk","year":"2021","journal-title":"J Subst Abuse Treat"},{"key":"2025083005212371200_qxaf157-B38","volume-title":"Key Substance Use and Mental Health Indicators in the United States: Results from the 2023 National Survey on Drug Use and Health","author":"SAMHSA","year":"2024"},{"key":"2025083005212371200_qxaf157-B39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4899-1934-2_1","volume-title":"Treating Addictive Behaviors, Applied Clinical Psychology","author":"DiClemente","year":"1998"},{"key":"2025083005212371200_qxaf157-B40","doi-asserted-by":"publisher","first-page":"112389","DOI":"10.1016\/j.drugalcdep.2024.112389","article-title":"Buprenorphine treatment and clinical outcomes under the opioid use disorder cascade of care","volume":"263","author":"Williams","year":"2024","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"2025083005212371200_qxaf157-B41","doi-asserted-by":"publisher","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2025083005212371200_qxaf157-B42","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13722-024-00516-z","article-title":"Strategies for improving treatment retention for buprenorphine\/naloxone for opioid use disorder: a qualitative study of issues and recommendations from prescribers","volume":"19","author":"Young","year":"2024","journal-title":"Addict Sci Clin Pract"},{"key":"2025083005212371200_qxaf157-B43","volume-title":"2022 Behavioral Health Workforce Assessment: A Report of the Behavioral Health Workforce Advisory Committee","author":"Boyd","year":"2022"},{"key":"2025083005212371200_qxaf157-B44","volume-title":"Heroin and Fentanyl in Washington State","author":"Addictions, Drug & Alcohol Institute (ADAI)"},{"issue":"10","key":"2025083005212371200_qxaf157-B45","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1111\/add.15954","article-title":"Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine\/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial","volume":"117","author":"Socias","year":"2022","journal-title":"Addiction"},{"issue":"4","key":"2025083005212371200_qxaf157-B46","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1097\/ADM.0000000000000922","article-title":"Evidence of buprenorphine-precipitated withdrawal in persons who use fentanyl","volume":"16","author":"Varshneya","year":"2022","journal-title":"J Addict Med"},{"issue":"9","key":"2025083005212371200_qxaf157-B47","doi-asserted-by":"publisher","first-page":"e2334540","DOI":"10.1001\/jamanetworkopen.2023.34540","article-title":"Buprenorphine dose and time to discontinuation among patients with opioid use disorder in the era of fentanyl","volume":"6","author":"Chambers","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2025083005212371200_qxaf157-B48","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1176\/appi.ajp.20230273","article-title":"Fentanyl and other opioid use disorders: treatment and research needs","volume":"180","author":"Volkow","year":"2023","journal-title":"Am J Psychiatry"},{"key":"2025083005212371200_qxaf157-B49","volume-title":"Unmet Needs, Complex Motivations, and Ideal Care for People Using Fentanyl in Washington State: A Qualitative Study","author":"Winstead","year":"2023"},{"issue":"3","key":"2025083005212371200_qxaf157-B50","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/ADM.0000000000001274","article-title":"Social determinants of health and continuity of medications for opioid use disorder among patients receiving treatment in rural primary care settings","volume":"18","author":"Pham","year":"2024","journal-title":"J Addict Med"},{"key":"2025083005212371200_qxaf157-B51","doi-asserted-by":"publisher","first-page":"209310","DOI":"10.1016\/j.josat.2024.209310","article-title":"Barriers to retention in medications for opioid use disorder treatment in real-world practice","volume":"160","author":"Villamil","year":"2024","journal-title":"J Subst Use Addict Treat"},{"issue":"2","key":"2025083005212371200_qxaf157-B52","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1177\/00220426231204841","article-title":"Trends and barriers of medication treatment for opioid use disorders: a systematic review and meta-analysis","volume":"55","author":"Hutchison","year":"2025","journal-title":"J Drug Issues"},{"key":"2025083005212371200_qxaf157-B53","doi-asserted-by":"publisher","first-page":"102240","DOI":"10.1016\/j.evalprogplan.2023.102240","article-title":"Identifying gender differences in risk profiles and in opioid treatment outcomes in Los Angeles County","volume":"97","author":"Amaro","year":"2023","journal-title":"Eval Program Plann"},{"key":"2025083005212371200_qxaf157-B54","doi-asserted-by":"publisher","first-page":"17455057231224181","DOI":"10.1177\/17455057231224181","article-title":"Pregnancy- and parenting-related barriers to receiving medication for opioid use disorder: a multi-paneled qualitative study of women in treatment, women who terminated treatment, and the professionals who serve them","volume":"20","author":"Apsley","year":"2024","journal-title":"Womens Health (Lond)"},{"key":"2025083005212371200_qxaf157-B55","doi-asserted-by":"publisher","first-page":"103803","DOI":"10.1016\/j.drugpo.2022.103803","article-title":"Medication for opioid use disorder treatment continuity post-release from jail: a qualitative study with community-based treatment providers","volume":"110","author":"Stopka","year":"2022","journal-title":"Int J Drug Policy"},{"issue":"1","key":"2025083005212371200_qxaf157-B56","doi-asserted-by":"publisher","first-page":"2355566","DOI":"10.1080\/07853890.2024.2355566","article-title":"The role of recovery peer navigators in retention in outpatient buprenorphine treatment: a retrospective cohort study","volume":"56","author":"Giraldo","year":"2024","journal-title":"Ann Med"},{"issue":"10","key":"2025083005212371200_qxaf157-B57","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/jamapsychiatry.2021.1969","article-title":"Contingency management for patients receiving medication for opioid use disorder: a systematic review and meta-analysis","volume":"78","author":"Bol\u00edvar","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"2025083005212371200_qxaf157-B58","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13722-024-00529-8","article-title":"Patient centered medication treatment for opioid use disorder in rural Vermont: a qualitative study","volume":"20","author":"Hichborn","year":"2025","journal-title":"Addict Sci Clin Pract"}],"container-title":["Health Affairs Scholar"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/advance-article-pdf\/doi\/10.1093\/haschl\/qxaf157\/63971674\/qxaf157.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article-pdf\/3\/8\/qxaf157\/63971674\/qxaf157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article-pdf\/3\/8\/qxaf157\/63971674\/qxaf157.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T09:21:29Z","timestamp":1756545689000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article\/doi\/10.1093\/haschl\/qxaf157\/8223953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":58,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/haschl\/qxaf157","relation":{},"ISSN":["2976-5390"],"issn-type":[{"value":"2976-5390","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,8]]},"article-number":"qxaf157"}}